Adani Power Fund Raise of ₹15,000 Cr

Adani Power Earnings Call Transcript: Key Takeaways

Adani Power delivered record Q2 results driven by robust demand and high plant availability. One-time revenue from Gujarat PPA and operational efficiency significantly boosted PAT.

Adani Power Investor Presentation: Key Takeaways

Q2 FY27 continuing revenue ₹17,528 Cr (+28.5% YoY), continuing EBITDA ₹6,321 Cr (+18.5%), PAT ₹7,019 Cr; reported PAT inflated by one-time income.

Adani Power Q2 FY27 Results: Net Profit ₹7,019 Cr, Up 141.5% YoY

Adani Power Ltd reported revenue from operations of ₹19,439 Cr (+44.5% YoY) and net profit of ₹7,019 Cr (+141.5% YoY) for Q2 FY27.

Key figure

Net profit ₹7,019 Cr · +141.5% YoY

Adani Power Bags New Order from Uttarakhand Power Corporation Limited

Adani Power received a Letter of Award from UPCL for 1,234 MW thermal power supply over 25 years. The LOA is subject to Uttarakhand ERC tariff approval.

From

Uttarakhand Power Corporation Limited (UPCL)

Execution

25 years

thermal power ex-bus net supply

1234 MW

Adani Power Capital Structure Change

GQG Partners LLC and PACs disclosed a net sale of Adani Power shares, reducing stake from 5.74% to 5.72%. The open-market disposal crosses the 2% disclosure threshold.

Adani Power Other Announcement

Adani Power Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr